Abstract
ABSTRACT: Medium chain acyl-CoA dehydrogenase deficiency (MCAD) is a defect in the mitochondrial oxidation of fatty acids. The disorder typically presents with episodes of vomiting and hypoglycemia, sometimes with changes in mental status and hepatic failure. These Reye's-like features may culminate in coma and death. Stress, intercurrent illness, and reaction to childhood immunization have been shown to precipitate acute metabolic episodes in MCAD patients. All cases are caused by mutations of the single MCAD gene on chromosome 1. Most clinically ascertained cases are caused by an A985G transition in exon 11. Here we report the preliminary findings of MCAD patients detected prospectively through a supplemental newborn screening program in Pennsylvania using tandem mass spectrometry. From the first 80,371 newborns screened we prospectively found nine babies with MCAD (1/8930) plus two additional newborns screened because of a previously known family history. Molecular analysis showed 56% of the detected patients to be compound heterozygotes for the A985G and a second mutation. This is in contrast to clinical retrospective studies which have found only 20% to be compound heterozygotes. We have identified two of the other mutations including a novel mutation (DG91/C92, 6-bp deletion) in one of our patients by using single-stranded conformation polymorphism (SSCP) and sequence analysis of conformers. Our results confirm that MCAD is one of the more common inborn errors of metabolism. The different mutation frequencies observed between retrospective clinical studies and our prospective newborn screening study suggest that clinical ascertainment may lead to preferential identification of the A985G mutation.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ziadeh, R., Hoffman, E., Finegold, D. et al. Medium Chain Acyl-CoA Dehydrogenase Deficiency in Pennsylvania: Neonatal Screening Shows High Incidence and Unexpected Mutation Frequencies. Pediatr Res 37, 675–678 (1995). https://doi.org/10.1203/00006450-199505000-00021
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199505000-00021
This article is cited by
-
The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study
Orphanet Journal of Rare Diseases (2016)
-
Functional studies of 18 heterologously expressed medium‐chain acyl‐CoA dehydrogenase (MCAD) variants
Journal of Inherited Metabolic Disease (2014)
-
Plasma fatty acids as diagnostic markers in autistic patients from Saudi Arabia
Lipids in Health and Disease (2011)
-
The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario
BMC Pediatrics (2010)
-
Fatty acid oxidation disorders: outcome and long‐term prognosis
Journal of Inherited Metabolic Disease (2010)